Evaxion establishes new AI-derived precision cancer vaccine concept Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the inventionUnique Attributes and...

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to...